Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 5,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Agent Clear all

Conditions: Healthy Volunteer
Interventions: GSK1349572, Atazanavir 300 mg, Atazanavir 400 mg, Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Participants
Interventions: BMS-986322, Loestrin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Anaheim, California

Conditions: Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage IV Colon Cancer AJCC V8, Stage IV Colorectal Cancer AJCC V8, Stage IV Rectal Cancer AJCC V8
Interventions: Trastuzumab, Trifluridine and Tipiracil Hydrochloride, Tucatinib; Biological · Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: San Diego, California • Durham, North Carolina

Conditions: Bacterial Infections
Interventions: Clindamycin, trimethoprim-sulfamethoxazole; Drug
Lead sponsor: Michael Cohen-Wolkowiez; Other
Eligibility: 1 Month to 16 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 3
States / cities: Little Rock, Arkansas • Chicago, Illinois • Ann Arbor, Michigan

Conditions: HIV Infections
Interventions: Saquinavir, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more

Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions: CPI-1205, Cobicistat, Enzalutamide, Abiraterone, Prednisone; Drug
Lead sponsor: Constellation Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 41
States / cities: Anchorage, Alaska • Beverly Hills, California • Duarte, California + 34 more

Conditions: Advanced Solid Tumors
Interventions: BLZ945, PDR001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts • Nashville, Tennessee • Houston, Texas + 1 more

Conditions: Prostate Cancer
Interventions: ezetimibe 10mg-simvastatin 40mg; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Renal Cell Carcinoma
Interventions: CTT1057; Drug
Lead sponsor: Cancer Targeted Technology; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Drug Interactions, Drug Kinetics
Interventions: Alprazolam, Oxycodone, Placebo; Drug
Lead sponsor: Shanna Babalonis, PhD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Chronic Hepatitis B
Interventions: FTC/TDF, Hepatitis B Immunoglobulin (HBIg); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 52
States / cities: Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 47 more

Conditions: Adult Ovarian Granulosa Cell Tumor
Interventions: Biospecimen Collection, Chest Radiography, Computed Tomography, Darolutamide, Exemestane, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 66
States / cities: Los Angeles, California • Newark, Delaware • Boise, Idaho + 55 more

Conditions: Epithelial Ovarian Cancer
Interventions: Farletuzumab, Carboplatin, and PLD; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Birmingham, Alabama • Baltimore, Maryland • Brightwaters, New York + 2 more

Conditions: HIV Infections
Interventions: Emtricitabine/ tenofovir disoproxil fumarate, Lopinavir/Ritonavir; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 25
States / cities: San Diego, California • San Francisco, California • Torrance, California + 16 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Bemcentinib, Cytarabine, Decitabine; Drug
Lead sponsor: BerGenBio ASA; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 2
States / cities: Iowa City, Iowa • Houston, Texas

Conditions: Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions: TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 9 more

Conditions: Long COVID, Long Covid19, Long Covid-19
Interventions: IVIG + Coordinated Care, IVIG Placebo + Coordinated Care, Ivabradine + Coordinated Care, Ivabradine Placebo + Coordinated Care, IVIG + Usual Care, IVIG Placebo + Usual Care, Ivabradine + Usual Care, Ivabradine Placebo + Usual Care; Drug
Lead sponsor: Kanecia Obie Zimmerman; Other
Eligibility: 18 Years and older
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 50
States / cities: Opelika, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: PF-08052667, Sasanlimab, BCG, PF-02921367; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 55
States / cities: Birmingham, Alabama • Ruskin, Florida • Tampa, Florida + 21 more

Conditions: Photodynamic Therapy, Microvesicle Particle
Interventions: Photodynamic Therapy, 4% Imipramine, Base Cream; Device · Drug
Lead sponsor: Wright State University; Other
Eligibility: 21 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Fairborn, Ohio

Conditions: HIV/AIDS, HIV Prevention
Interventions: Tenofovir Douche; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Renal Failure Chronic, Hepatitis C
Interventions: Zepatier, Zepatier plus Sofosbuvir; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Limited Stage Small Cell Lung Cancer
Interventions: Ociperlimab, Tislelizumab, Concurrent Chemoradiotherapy; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 23
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 15 more

Search by objective public record fields.

GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir

A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children

A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal

CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma

Opioid Drug Interaction Study

Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

RECOVER-AUTONOMIC Platform Protocol

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Photodynamic Therapy and Microvesicles

Evaluating Distribution of a Tenofovir Douche With Tap Water Douching and Simulated Receptive Anal Intercourse

Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS